Influenza outbreak

The Hindu Business Line  31 min ago  Comment 
Doctors expected the rise in mercury levels to lower intensity of swine flu incidence in Telangana, Andhra Pradesh and elsewhere in the country in the last week. But this did not happen on the exp...
The Times of India  Feb 15  Comment 
The outbreak of swine flu in Rajasthan and Maharashtra is expected to result in a loss of Rs 5,500 crore to tourism and aviation industries, according to an Assocham assessment.
The Hindu Business Line  Feb 13  Comment 
The distribution of swine flu medicines is being hampered in States with high incidence of the influenza because of the few licensed retailers. The Centre, however, is likely to consider...
The Hindu Business Line  Feb 12  Comment 
Thirty nine fresh cases of swine flu have been reported in Telangana which recorded 42 deaths since January 1 this year, a bulletin issued by the state government said here today.“In the cu...
The Hindu Business Line  Feb 9  Comment 
Telangana has made a pig’s ear of tackling swine flu
The Hindu Business Line  Feb 9  Comment 
Swine flu has claimed 23 lives in Punjab and Haryana this winter, officials said here today.Punjab’s nodal officer Dr Deepak Bhatia said that the H1N1 virus has claimed 12 lives till date in...
FiercePharma  Feb 9  Comment 
SINGAPORE--The head of Guinea's Ebola-response program wasted no time in announcing approval of broader use of Fujifilm's Avigan (favipiravir) influenza drug for treating early cases of Ebola in the West Africa nation.
Motley Fool  Feb 8  Comment 
Based on the latest update from the Centers for Disease Control and Prevention, the worst of the 2014-2015 flu season may be behind us.
The Hindu Business Line  Feb 8  Comment 
The national capital today recorded the sixth death due to swine flu with a 55—year—old man succumbing to H1N1 virus at a private hospital here.“He was tested positive for swine flu and was...
FierceBiotech  Feb 6  Comment 
SINGAPORE--Fujifilm's Toyama Chemical is readying a study for a scientific journal stating that its Avigan (favipiravir) influenza drug has shown promise in treating ebolavirus so far in an early-phase clinical trial in the West African country of...


Influenza, or the flu, is a common infectious disease, which can be deadly to individuals with compromised immune systems (the very young, the very old, and those with conditions such as AIDS or Cancer). However, occasionally particularly virulent strains of influenza break out that can be threatening on a much larger scale -- such as the flu epidemic of 1918 and, more recently, concerns that H5N1 "Bird Flu" or H1N1 "Swine Flu" could mutate into a highly-infectious and deadly virus. A number of pharmaceutical companies make treatments for the flu and benefit from the fear of a flu outbreak.

  • Roche Pharmaceuticals makes Tamiflu, an antiviral pill to treat the flu. In 2005, amid concerns that bird flu might pose a large threat during the winter flu season, many national governments began stocking up on Tamiflu. Chugai pharmaceuticals sells Tamiflu in Japan.
  • Novartis AG (NVS), through its acquisition of Chiron in 2006, supplies much of the traditional flu vaccine supply to the United States.
  • AstraZeneca (AZN), through recently acquired MedImmune, manufactures 'FluMist', a novel flu vaccine that is delivered via an intranasal spray rather than via an injection.

Companies with treatments for H1N1, or "Swine Flu"

In April 2009, a novel flu virus, known as "Swine Flu" because it was believed to have originated in pigs, started infecting humans. By April 28th, there were 1,300 confirmed cases of the flu, known by its scientific designation H1N1, in Mexico, and a handful in the U.S. and other parts of the world.

According to preliminary test done by the US Center for Disease Control, Roche Pharmaceuticals (RHHBY)'s Tamiflu and GlaxoSmithKline (GSK)'s Relenza are active against H1N1, although many older drugs are not. [1]


  1. Investors buy up shares of flu drug makers, New York Times, April 27th 2009.
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki